StockNews.AI
AMGN
StockNews.AI
104 days

Amgen's TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom

1. Amgen's TEPEZZA receives marketing authorization in the UK for Thyroid Eye Disease. 2. This authorisation targets 50,000 patients suffering from a serious condition.

2m saved
Insight
Article

FAQ

Why Bullish?

The approval of TEPEZZA could significantly increase Amgen's revenue, similar to past drug launches. Historical precedents show successful market entries boosting stock prices in biotech.

How important is it?

This milestone can enhance Amgen's market position and drive future sales growth, particularly in an underserved patient population.

Why Long Term?

The market authorization can lead to sustained revenue, impacting growth over the coming years, akin to successful treatments gaining traction.

Related Companies

BIIBABBVVRTX
CAMBRIDGE, England--(BUSINESS WIRE)--Today, Amgen announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for TEPEZZA® (teprotumumab) as the first therapy specifically licensed for the treatment of adult patients with moderate-to-severe Thyroid Eye Disease (TED). Affecting approximately 50,000 people in the UK,1 TED is a progressive and potentially vision-threatening condition, which can cause eye bulging, double vision, eye pain, r.

Related News